Da remiziramo...
Page 35 of 50
Page 35 of 50 • 1 ... 19 ... 34, 35, 36 ... 42 ... 50
Re: Da remiziramo...
Sovak wrote:Eroo wrote:venus wrote:Eroo wrote:Eroo wrote:
@Venus, upravo gledam jučerašnje rezultate po županijama. U VŽ vidim rezultat koji ne paše u "sistem", kao da im se je dogodio neki veći incident (lokalni klaster): +627 novozaraženih. Rezultat bi trebao biti ispod +250. Već danas bi moglo biti jasno o čemu se radi.
Pratimo dalje...
@Venus
Dobra prognoza
Pratim!
Šampanjac bi mogao doći na red prije nego što sam mislio.
A graf .... nikaj?
Graf o ukupnom broju postoji na službenoj stranici. Ostalo bi morao sam crtat, ali ne vidim smisla.
Venus otvara šapanjac na rezultat +80, a ja ću poslati čestitku Čačiću za dobro odglumljen posao.
Eroo- Posts : 79090
2016-07-22
Re: Da remiziramo...
Eroo wrote:Sovak wrote:Eroo wrote:venus wrote:Eroo wrote:Eroo wrote:
@Venus, upravo gledam jučerašnje rezultate po županijama. U VŽ vidim rezultat koji ne paše u "sistem", kao da im se je dogodio neki veći incident (lokalni klaster): +627 novozaraženih. Rezultat bi trebao biti ispod +250. Već danas bi moglo biti jasno o čemu se radi.
Pratimo dalje...
@Venus
Dobra prognoza
Pratim!
Šampanjac bi mogao doći na red prije nego što sam mislio.
A graf .... nikaj?
Graf o ukupnom broju postoji na službenoj stranici. Ostalo bi morao sam crtat, ali ne vidim smisla.
Venus otvara šapanjac na rezultat +80, a ja ću poslati čestitku Čačiću za dobro odglumljen posao.
_________________
Nulla rosa sine spina
Eroo- Posts : 79090
2016-07-22
Re: Da remiziramo...
Idem si narezat špek ... baš mi treba ... žuja mi otvorila tek.
Kumpanija ... se pišemo.
Bok.
Kumpanija ... se pišemo.
Bok.
Guest- Guest
Re: Da remiziramo...
i Hrvati!Sovak wrote:Idem si narezat špek ... baš mi treba ... žuja mi otvorila tek.
Kumpanija ... se pišemo.
Bok.
dijagram-
Posts : 18938
2015-08-09
Re: Da remiziramo...
i ovi iz ormaradijagram wrote:i Hrvati!Sovak wrote:Idem si narezat špek ... baš mi treba ... žuja mi otvorila tek.
Kumpanija ... se pišemo.
Bok.
_________________
AfD
veber-
Posts : 53509
2014-12-30
Re: Da remiziramo...
Eroo wrote:Gnječ wrote:opet namaz samopromocije pa namaz budalaština pa opet dvi fete samopromocije...
Ne vjerujem da si ti Foe, ali da si i zapao u loše drušvo to jesi. Čopor.
nisam zapao nigdje. ti si vješt manipulator ali više mi se ne da elaborirati jer si naporan, iskačeš iz svake paštete, neodgojen si pripadnik ercegovnjarske talibanske sirotinje, napoleonski sindrom, narcisoidni poremećaj ličnosti, udbaš, šetebandiere... to je moja odokativna dijagnoza. malo skromnosti ti ne bi škodilo.
Guest- Guest
Re: Da remiziramo...
Eroo wrote:Eroo wrote:Sovak wrote:Eroo wrote:venus wrote:Eroo wrote:Eroo wrote:
@Venus, upravo gledam jučerašnje rezultate po županijama. U VŽ vidim rezultat koji ne paše u "sistem", kao da im se je dogodio neki veći incident (lokalni klaster): +627 novozaraženih. Rezultat bi trebao biti ispod +250. Već danas bi moglo biti jasno o čemu se radi.
Pratimo dalje...
@Venus
Dobra prognoza
Pratim!
Šampanjac bi mogao doći na red prije nego što sam mislio.
A graf .... nikaj?
Graf o ukupnom broju postoji na službenoj stranici. Ostalo bi morao sam crtat, ali ne vidim smisla.
Venus otvara šapanjac na rezultat +80, a ja ću poslati čestitku Čačiću za dobro odglumljen posao.
_________________
Nulla rosa sine spina
Eroo- Posts : 79090
2016-07-22
Re: Da remiziramo...
znam da ti auto treba.Legendovich wrote:veber wrote:to govori o tvojem "znanju" jednog "inžinjera"Legendovich wrote:Jeboteirud,tamo crta neke vijkove propelere.kuratz palatz a ovdi mogli pare zaraditi i biti bougati..Feberu,udaraj glavom o zid..
ja sam školovan, školovao sam se i školovat ću se.
ta "elisa" na propulzijskom dizelskom motoru smanjuje potrošnju od 3%, nema kavitacije, buka je smanjena.
ovo tebi izgleda, vjerovatno kao svrdlo, ali to je šesteroperni brodski vijak s asimetričnim nagibom lopatica.
trenutno prototipan.
razlika je da ti voziš mitshubishi, a ja astru ;)
Pa meni je auto potreba,ne kurcenje..da se kurcim kao ti,ne bi vozio srebrni bembac limuzinu,nego XC90,bijeli..ti si fakat,kao bosanac..
i da moraš s bauštele na bauštelu saubermaher biti.
znači imaš fetiš na XLL90?
ma, ok. bolje veliki u dupetu nego mali na parkingu.
svatko ima neke svoje preference.
_________________
AfD
veber-
Posts : 53509
2014-12-30
Re: Da remiziramo...
Pa kad sam superioran, jebiga...Ma ne misli da san ja za to zaslužan, daleko od toga. A nisan ni kriv...Gnječ wrote:Eroo wrote:Gnječ wrote:opet namaz samopromocije pa namaz budalaština pa opet dvi fete samopromocije...
Ne vjerujem da si ti Foe, ali da si i zapao u loše drušvo to jesi. Čopor.
nisam zapao nigdje. ti si vješt manipulator ali više mi se ne da elaborirati jer si naporan, iskačeš iz svake paštete, neodgojen si pripadnik ercegovnjarske talibanske sirotinje, napoleonski sindrom, narcisoidni poremećaj ličnosti, udbaš, šetebandiere... to je moja odokativna dijagnoza. malo skromnosti ti ne bi škodilo.
_________________
Nulla rosa sine spina
Eroo- Posts : 79090
2016-07-22
Re: Da remiziramo...
Eroo wrote:Eroo wrote:Eroo wrote:Sovak wrote:Eroo wrote:venus wrote:Eroo wrote:Eroo wrote:
@Venus, upravo gledam jučerašnje rezultate po županijama. U VŽ vidim rezultat koji ne paše u "sistem", kao da im se je dogodio neki veći incident (lokalni klaster): +627 novozaraženih. Rezultat bi trebao biti ispod +250. Već danas bi moglo biti jasno o čemu se radi.
Pratimo dalje...
@Venus
Dobra prognoza
Pratim!
Šampanjac bi mogao doći na red prije nego što sam mislio.
A graf .... nikaj?
Graf o ukupnom broju postoji na službenoj stranici. Ostalo bi morao sam crtat, ali ne vidim smisla.
Venus otvara šapanjac na rezultat +80, a ja ću poslati čestitku Čačiću za dobro odglumljen posao.
_________________
Nulla rosa sine spina
Eroo- Posts : 79090
2016-07-22
Re: Da remiziramo...
fulao si u jednom. nije manipulator, što bi htio biti.Gnječ wrote:Eroo wrote:Gnječ wrote:opet namaz samopromocije pa namaz budalaština pa opet dvi fete samopromocije...
Ne vjerujem da si ti Foe, ali da si i zapao u loše drušvo to jesi. Čopor.
nisam zapao nigdje. ti si vješt manipulator ali više mi se ne da elaborirati jer si naporan, iskačeš iz svake paštete, neodgojen si pripadnik ercegovnjarske talibanske sirotinje, napoleonski sindrom, narcisoidni poremećaj ličnosti, udbaš, šetebandiere... to je moja odokativna dijagnoza. malo skromnosti ti ne bi škodilo.
on ima klasični sindrom odbacivanja iz čopora, a sam ne može kao jedinka.
_________________
AfD
veber-
Posts : 53509
2014-12-30
Re: Da remiziramo...
Eroo wrote:Pa kad sam superioran, jebiga...Ma ne misli da san ja za to zaslužan, daleko od toga. A nisan ni kriv...Gnječ wrote:Eroo wrote:Gnječ wrote:opet namaz samopromocije pa namaz budalaština pa opet dvi fete samopromocije...
Ne vjerujem da si ti Foe, ali da si i zapao u loše drušvo to jesi. Čopor.
nisam zapao nigdje. ti si vješt manipulator ali više mi se ne da elaborirati jer si naporan, iskačeš iz svake paštete, neodgojen si pripadnik ercegovnjarske talibanske sirotinje, napoleonski sindrom, narcisoidni poremećaj ličnosti, udbaš, šetebandiere... to je moja odokativna dijagnoza. malo skromnosti ti ne bi škodilo.
Šteta što te svi ne gledamo tvojim očima. :)
Ra- Posts : 2324
2020-06-01
Re: Da remiziramo...
Sovak wrote:Eroo wrote:venus wrote:Eroo wrote:Eroo wrote:
@Venus, upravo gledam jučerašnje rezultate po županijama. U VŽ vidim rezultat koji ne paše u "sistem", kao da im se je dogodio neki veći incident (lokalni klaster): +627 novozaraženih. Rezultat bi trebao biti ispod +250. Već danas bi moglo biti jasno o čemu se radi.
Pratimo dalje...
@Venus
Dobra prognoza
Pratim!
Šampanjac bi mogao doći na red prije nego što sam mislio.
A graf .... nikaj?
Evo, tu ti je Hrvatski. Za one koji računaju na prste itako su nebitni.
Last edited by Eroo on 8/12/2020, 21:29; edited 1 time in total
_________________
Nulla rosa sine spina
Eroo- Posts : 79090
2016-07-22
Re: Da remiziramo...
znači u klubu luzera, ero je vođa čopora, ti si mu upravo stavio njušku pod rep.Legendovich wrote:Ero vas pali,a to ne kuzite..
ili?
_________________
AfD
veber-
Posts : 53509
2014-12-30
Re: Da remiziramo...
Eroo wrote:Pa kad sam superioran, jebiga...Ma ne misli da san ja za to zaslužan, daleko od toga. A nisan ni kriv...Gnječ wrote:Eroo wrote:Gnječ wrote:opet namaz samopromocije pa namaz budalaština pa opet dvi fete samopromocije...
Ne vjerujem da si ti Foe, ali da si i zapao u loše drušvo to jesi. Čopor.
nisam zapao nigdje. ti si vješt manipulator ali više mi se ne da elaborirati jer si naporan, iskačeš iz svake paštete, neodgojen si pripadnik ercegovnjarske talibanske sirotinje, napoleonski sindrom, narcisoidni poremećaj ličnosti, udbaš, šetebandiere... to je moja odokativna dijagnoza. malo skromnosti ti ne bi škodilo.
šupčino, nisi superioran nego si mediokritet. oni koji su superiorni i znaju da su superiorni ponašaju se vrlo ponizno i skromno skroz normalno a ne superiorno ni arogantno to jedino rade mediokriteti. mediokriteti su ti koji stalno traže priznanje, aplauz stalno okolinu podsjećaju da su "superiorni" a takvo je ponašanje iritantno.
Last edited by Gnječ on 8/12/2020, 21:34; edited 1 time in total
Guest- Guest
Re: Da remiziramo...
Ne bi ni valjalo da svi gledate s mojim očima.Ra wrote:Eroo wrote:Pa kad sam superioran, jebiga...Ma ne misli da san ja za to zaslužan, daleko od toga. A nisan ni kriv...Gnječ wrote:Eroo wrote:Gnječ wrote:opet namaz samopromocije pa namaz budalaština pa opet dvi fete samopromocije...
Ne vjerujem da si ti Foe, ali da si i zapao u loše drušvo to jesi. Čopor.
nisam zapao nigdje. ti si vješt manipulator ali više mi se ne da elaborirati jer si naporan, iskačeš iz svake paštete, neodgojen si pripadnik ercegovnjarske talibanske sirotinje, napoleonski sindrom, narcisoidni poremećaj ličnosti, udbaš, šetebandiere... to je moja odokativna dijagnoza. malo skromnosti ti ne bi škodilo.
Šteta što te svi ne gledamo tvojim očima. :)
Nije u pitanju dioptrija, o nečem drugom je riječ...
Jednom ćete se i vi morati odlučiti između carpe diem i memento mori, ili možda i nećete...stvar izbora.
A možda i kućnog ne/odgoja.
_________________
Nulla rosa sine spina
Eroo- Posts : 79090
2016-07-22
Re: Da remiziramo...
cemu takva negativa...nisam niti za Eru,niti protiv..da me takav lik uspije podici na straznje,ja bi se zabrinuo za svoj menthalni nivo..cisto ga registriram,ne citam sto pise ili stavlja to je to..veber wrote:znači u klubu luzera, ero je vođa čopora, ti si mu upravo stavio njušku pod rep.Legendovich wrote:Ero vas pali,a to ne kuzite..
ili?
Guest- Guest
Re: Da remiziramo...
Jesam, jebiga...Gnječ wrote:Eroo wrote:Pa kad sam superioran, jebiga...Ma ne misli da san ja za to zaslužan, daleko od toga. A nisan ni kriv...Gnječ wrote:Eroo wrote:Gnječ wrote:opet namaz samopromocije pa namaz budalaština pa opet dvi fete samopromocije...
Ne vjerujem da si ti Foe, ali da si i zapao u loše drušvo to jesi. Čopor.
nisam zapao nigdje. ti si vješt manipulator ali više mi se ne da elaborirati jer si naporan, iskačeš iz svake paštete, neodgojen si pripadnik ercegovnjarske talibanske sirotinje, napoleonski sindrom, narcisoidni poremećaj ličnosti, udbaš, šetebandiere... to je moja odokativna dijagnoza. malo skromnosti ti ne bi škodilo.
šupčino, nisi superioran nego si mediokritet. oni koji su superiorni i znaju da su superiorni ponašaju se vrlo ponizno i skromno skroz normalno a ne superiorno ni arogantno to jedino rade mediokriteti. mediokriteti su ti koji stalno traže priznanje, aplauz stalno okolinu podsjećaju da su "superiorni" a takvo je ponašanje iritantno.
Na internetu su moje neke reference. Možemo ovdje postavit kopiju, svak od svojih...
Čivavi iznad tebe sam ih postavio, ali nije on svoje.
On i dalje računa s elektrodama...znaš ono, postavi 4, jednu pored druge i s 5.-om prekriži s dijagonalom.
_________________
Nulla rosa sine spina
Eroo- Posts : 79090
2016-07-22
Re: Da remiziramo...
dobro..evo malo zanimljivog stiva,sa jucerasnjeg vrlo dobrog linka..nanotech vs. Sars-Cov2..
[size=39]Nanotechnology versus coronavirus
Nature Nanotechnology volume 15, page617(2020)Cite this article
[/size]
In the face of the coronavirus pandemic, it is time for the nanotechnology community to shine and build on its experience with nanoscale materials and drug delivery to provide knowledge and tools for COVID-19 vaccine and therapeutics development.
While many parts of the world remain in lockdown and universities are closed, numerous nanotechnology research labs have kept open throughout the last months to redirect their efforts towards the development of a vaccine and/or nanoformulations of therapeutics for the treatment of COVID-19. Expertise in nucleic acid and drug delivery, cancer nanovaccines, immunoengineering, nanotechnology-based sensors and platform technologies positions nanotechnology in a unique place to tackle some of the key issues in pre-clinical and clinical COVID-19 research. After all, viruses are naturally occurring nanoparticles, and indeed, the nanotechnology community has long been trying to capitalize on the properties of viruses and mimic their behaviour, for example, for the design of virus-like nanoparticles for targeted drug delivery and gene editing.
In this Focus issue, nanotechnologists from different areas discuss ongoing efforts in COVID-19 vaccine development, the potential advantages of nanoformulations for the most promising therapeutic candidates, nanotechnological tools that may facilitate worldwide vaccine manufacturing and distribution, and nanomaterial-based viral disinfectants and detection platforms.
Vaccines are the most promising solution to mitigate the spread of the coronavirus SARS-CoV-2. Nanomaterials play an important role in all aspects of vaccine design, delivery and administration. Nanoparticles enable multivalent antigen presentation and stabilization of antigens upon administration, they can serve as adjuvants to boost the immune response, and they can act as carriers for the targeted delivery of antigens. Indeed, an mRNA vaccine delivered by a liposomal nanoparticle is amongst the candidates currently in clinical trials against SARS-CoV-2. While it remains a fact that no mRNA or DNA vaccine is currently approved for any disease, the delivery of nucleic acids requires some form of modification or a nanodevice to prevent degradation in the body, and liposomal devices have indeed already been approved for RNA delivery, albeit not yet for vaccines. The nanotechnology community has further gained immense knowledge over the past years in the development of cancer nanovaccines to boost and/or reprogram host immunity, which may now provide a solid starting point for immune-mediated approaches against SARS-CoV-2.
Importantly, nanomaterial-based platform technologies may also play a key role in the distribution and administration of vaccines in resource-poor or densely populated developing countries by enabling self-administration, for example, through microneedle patches, single-dose slow-release implants, film-based vaccines, or by using plant viral nanoparticles for antigen delivery, which do not require cold chains. In a global pandemic, in which healthcare systems are operating at the limit, such self-administration technologies may prove extremely valuable. Cold chain requirements can also be circumvented by applying alternative production platforms, such as molecular farming in plants. Thereby, vaccines are produced in edible leaf tissue for the vaccination of humans and livestock.
From a therapeutic standpoint, the repurposing of existing drugs is currently at the centre of research owing to a lack of new therapeutic treatments against COVID-19. So far, only a few drugs have demonstrated efficacy against COVID-19 in clinical trials. The anti-inflammatory corticosteroid dexamethasone has recently been shown to have life-saving efficacy in a clinical trial. Dexamethasone has previously been formulated as a nanomedicine for the treatment of other diseases; for example, liposomal dexamethasone has shown efficacy in multiple myeloma. In the case of COVID-19, a nanomedicine formulation may enable the targeting of alveolar macrophages upon pulmonary delivery or of phagocytes at inflammation sites following intravenous administration. Moreover, the anti-fibrotic effects of dexamethasone can be potentiated by reformulating it as a nanomedicine. The argument can be made, of course, that a nanoformulation will make the therapy even more expensive (not even speaking of the need for additional clinical trials); however, if such nanoformulation improves clinical outcomes, and thus, would allow critically ill patients to leave the intensive care unit earlier, the cost reduction in hospitalization and faster patient recovery may be well worth it.
A main reason for the ongoing repurposing of drugs and fast-tracking of preclinical and clinical testing of vaccine formulations for COVID-19, is the lack of time. The development, clinical testing and approval of new drugs usually take years. Therefore, in the future, it will be important to scientifically and financially invest in platform technologies that can then be rapidly repurposed on demand, to be better prepared for future outbreaks — a lesson (hopefully) learned from the current pandemic. Nanodevices and nanoformulations offer such platform technologies, and a thorough investigation of their fundamental science and biological interactions will be of great value for the future development of vaccines and therapeutics.
Facing the SARS-CoV-2 pandemic, the nanotechnology community has joined forces and provides their tools and experience to the COVID-19 research efforts. There has been criticism about the clinical impact of nanotechnology, but the time has now come to highlight the knowledge and previous experience of nanotechnologists in vaccine and drug development, delivery and distribution. The ongoing research efforts and collaborations with the clinic and industry will hopefully have an impact on the future of our field to further open the way for the clinical translation of nanotechnology. However, while lockdowns are starting to be eased, let us not forget that a vaccine may still be far away from clinical reality and that the road from preclinical testing to clinical efficacy can be long and bumpy — a fact that the nanotechnology community is well aware of.
https://www.nature.com/articles/s41565-020-0757-7
[size=39]Nanotechnology versus coronavirus
Nature Nanotechnology volume 15, page617(2020)Cite this article
[/size]
- 11k Accesses
- 44 Altmetric
- Metricsdetails
In the face of the coronavirus pandemic, it is time for the nanotechnology community to shine and build on its experience with nanoscale materials and drug delivery to provide knowledge and tools for COVID-19 vaccine and therapeutics development.
While many parts of the world remain in lockdown and universities are closed, numerous nanotechnology research labs have kept open throughout the last months to redirect their efforts towards the development of a vaccine and/or nanoformulations of therapeutics for the treatment of COVID-19. Expertise in nucleic acid and drug delivery, cancer nanovaccines, immunoengineering, nanotechnology-based sensors and platform technologies positions nanotechnology in a unique place to tackle some of the key issues in pre-clinical and clinical COVID-19 research. After all, viruses are naturally occurring nanoparticles, and indeed, the nanotechnology community has long been trying to capitalize on the properties of viruses and mimic their behaviour, for example, for the design of virus-like nanoparticles for targeted drug delivery and gene editing.
In this Focus issue, nanotechnologists from different areas discuss ongoing efforts in COVID-19 vaccine development, the potential advantages of nanoformulations for the most promising therapeutic candidates, nanotechnological tools that may facilitate worldwide vaccine manufacturing and distribution, and nanomaterial-based viral disinfectants and detection platforms.
Vaccines are the most promising solution to mitigate the spread of the coronavirus SARS-CoV-2. Nanomaterials play an important role in all aspects of vaccine design, delivery and administration. Nanoparticles enable multivalent antigen presentation and stabilization of antigens upon administration, they can serve as adjuvants to boost the immune response, and they can act as carriers for the targeted delivery of antigens. Indeed, an mRNA vaccine delivered by a liposomal nanoparticle is amongst the candidates currently in clinical trials against SARS-CoV-2. While it remains a fact that no mRNA or DNA vaccine is currently approved for any disease, the delivery of nucleic acids requires some form of modification or a nanodevice to prevent degradation in the body, and liposomal devices have indeed already been approved for RNA delivery, albeit not yet for vaccines. The nanotechnology community has further gained immense knowledge over the past years in the development of cancer nanovaccines to boost and/or reprogram host immunity, which may now provide a solid starting point for immune-mediated approaches against SARS-CoV-2.
Importantly, nanomaterial-based platform technologies may also play a key role in the distribution and administration of vaccines in resource-poor or densely populated developing countries by enabling self-administration, for example, through microneedle patches, single-dose slow-release implants, film-based vaccines, or by using plant viral nanoparticles for antigen delivery, which do not require cold chains. In a global pandemic, in which healthcare systems are operating at the limit, such self-administration technologies may prove extremely valuable. Cold chain requirements can also be circumvented by applying alternative production platforms, such as molecular farming in plants. Thereby, vaccines are produced in edible leaf tissue for the vaccination of humans and livestock.
From a therapeutic standpoint, the repurposing of existing drugs is currently at the centre of research owing to a lack of new therapeutic treatments against COVID-19. So far, only a few drugs have demonstrated efficacy against COVID-19 in clinical trials. The anti-inflammatory corticosteroid dexamethasone has recently been shown to have life-saving efficacy in a clinical trial. Dexamethasone has previously been formulated as a nanomedicine for the treatment of other diseases; for example, liposomal dexamethasone has shown efficacy in multiple myeloma. In the case of COVID-19, a nanomedicine formulation may enable the targeting of alveolar macrophages upon pulmonary delivery or of phagocytes at inflammation sites following intravenous administration. Moreover, the anti-fibrotic effects of dexamethasone can be potentiated by reformulating it as a nanomedicine. The argument can be made, of course, that a nanoformulation will make the therapy even more expensive (not even speaking of the need for additional clinical trials); however, if such nanoformulation improves clinical outcomes, and thus, would allow critically ill patients to leave the intensive care unit earlier, the cost reduction in hospitalization and faster patient recovery may be well worth it.
A main reason for the ongoing repurposing of drugs and fast-tracking of preclinical and clinical testing of vaccine formulations for COVID-19, is the lack of time. The development, clinical testing and approval of new drugs usually take years. Therefore, in the future, it will be important to scientifically and financially invest in platform technologies that can then be rapidly repurposed on demand, to be better prepared for future outbreaks — a lesson (hopefully) learned from the current pandemic. Nanodevices and nanoformulations offer such platform technologies, and a thorough investigation of their fundamental science and biological interactions will be of great value for the future development of vaccines and therapeutics.
Facing the SARS-CoV-2 pandemic, the nanotechnology community has joined forces and provides their tools and experience to the COVID-19 research efforts. There has been criticism about the clinical impact of nanotechnology, but the time has now come to highlight the knowledge and previous experience of nanotechnologists in vaccine and drug development, delivery and distribution. The ongoing research efforts and collaborations with the clinic and industry will hopefully have an impact on the future of our field to further open the way for the clinical translation of nanotechnology. However, while lockdowns are starting to be eased, let us not forget that a vaccine may still be far away from clinical reality and that the road from preclinical testing to clinical efficacy can be long and bumpy — a fact that the nanotechnology community is well aware of.
https://www.nature.com/articles/s41565-020-0757-7
Guest- Guest
Page 35 of 50 • 1 ... 19 ... 34, 35, 36 ... 42 ... 50
Page 35 of 50
Permissions in this forum:
You cannot reply to topics in this forum